DBV Technologies: $229M in Cash to Fund Operations Until Q2 2027
DBV Technologies reports a cash position of $229 million as of March 31, 2026, funded by the full exercise of warrants from the private placement in March 2025. This liquidity position covers the needs until the second quarter of 2027, while the French biotech awaits a critical decision from the US regulator for its pediatric anti-allergen patch.
DBV Technologies has $229 million in cash and cash equivalents as of March 31, 2026. This amount reflects the full exercise of the ABSA and BS warrants from the private placement in March 2025. According to the company, this cash reserve provides funding covering up to the second quarter of 2027 at the current burn rate. The timeline aligns with key milestones in the US regulatory calendar.
Regulatory Milestones Take Precedence Over Operational Results
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Focus is on two imminent milestones. DBV Technologies aims to file a Biologics License Application (BLA) in the first half of 2026 for its VIASKIN Peanut Patch for children aged 4 to 7 years. Concurrently, the company continues its commercial preparations in anticipation of potential market launch in the United States, subject to regulatory approval. This transition phase from clinical stage to commercialization concentrates resources and shapes the company's outlook.
Disciplined Execution Amid Regulatory Risks
DBV Technologies emphasizes a disciplined execution strategy focused on regulatory filing and commercial preparation. The risk profile remains dominated by dependence on US regulatory approval. An unfavorable decision from the FDA could accelerate the consumption of available cash, while approval would initiate an unprecedented commercial cycle for the biotech.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
